PURPOSE: To study the potential relationship between circulating follicle-stimulating hormone (FSH) gonadotrophin, inhibin B, spermatogenesis and the benefit of highly purified urinary FSH (uFSH-HP) treatment in men with oligozoospermia. METHODS: Twenty-nine normogonadotropic, normogonadal men with oligozoospermia were evaluated. Serum hormonal concentration and spermiogram were analyzed before and after 3-month treatment with uFSH-HP. RESULTS: Our results support the hypothesis that inhibin B is involved in the physiological regulation of FSH secretion and reflects the FSH-stimulated Sertoli cell function. After treating with uFSH-HP for 3 months a significant increase in all semen parameters was observed in most of the patients. CONCLUSIONS: Although the benefit of inhibin B as a prognosis factor in oligozoospermic patients treated with FSH is not defined, it can be considered as an important serum marker in reproductive and testicular functions. Treatment of oligozoospermic patients with uFSH-HP has shown to be an effective and safe therapy.
PURPOSE: To study the potential relationship between circulating follicle-stimulating hormone (FSH) gonadotrophin, inhibin B, spermatogenesis and the benefit of highly purified urinary FSH (uFSH-HP) treatment in men with oligozoospermia. METHODS: Twenty-nine normogonadotropic, normogonadal men with oligozoospermia were evaluated. Serum hormonal concentration and spermiogram were analyzed before and after 3-month treatment with uFSH-HP. RESULTS: Our results support the hypothesis that inhibin B is involved in the physiological regulation of FSH secretion and reflects the FSH-stimulated Sertoli cell function. After treating with uFSH-HP for 3 months a significant increase in all semen parameters was observed in most of the patients. CONCLUSIONS: Although the benefit of inhibin B as a prognosis factor in oligozoospermic patients treated with FSH is not defined, it can be considered as an important serum marker in reproductive and testicular functions. Treatment of oligozoospermic patients with uFSH-HP has shown to be an effective and safe therapy.
Authors: A Barbonetti; A E Calogero; G Balercia; A Garolla; C Krausz; S La Vignera; F Lombardo; E A Jannini; M Maggi; A Lenzi; C Foresta; A Ferlin Journal: J Endocrinol Invest Date: 2018-02-01 Impact factor: 4.256
Authors: Rossella Cannarella; Sandro La Vignera; Rosita A Condorelli; Laura M Mongioì; Aldo E Calogero Journal: Asian J Androl Date: 2020 May-Jun Impact factor: 3.285
Authors: Rosita A Condorelli; Aldo E Calogero; Enzo Vicari; Laura Mongioi'; Giovanni Burgio; Rossella Cannarella; Filippo Giacone; Linda Iacoviello; Giuseppe Morgia; Vincenzo Favilla; Sebastiano Cimino; Sandro La Vignera Journal: Int J Endocrinol Date: 2014-01-14 Impact factor: 3.257